Analyst Upgrades

• Piper Jaffray upgraded MWI Veterinary Supply (MWIV) to overweight from neutral and raised its target for shares to $50.
• UBS believes Nokia (NOK) is well positioned for smartphone growth. The firm upgraded shares to buy from neutral and has a $19.55 price target.
• Wells Fargo upgraded Cedar Fair (FUN) to outperform from market perform. After the company's merger agreement with Apollo was terminated, the firm thinks the company will be able to refinance its debt, removing an uncertainty.
• Darden (DRI) was upgraded to outperform from neutral at Cowen.
• KeyCorp (KEY) was upgraded to buy from neutral at Goldman.
• Bank of Ireland (IRE) was upgraded to hold from sell at RBS.

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"One Chinese sector being relatively ignored by Wall Street is the biotech industry," notes Keith Fitz-Gerald. In The New China Trader, he looks to a biotech speculation -- Sinovac (AMEX: SVA).

"The government knows that the wheels could fall off the bike rather quickly if average Chinese citizens begin to see a dramatic reversal in their health and happiness.

Those surprised by the market's strength in recent weeks should be even more impressed with the rebound in China, where both their market and economy have proven among the most resilient in the world.

Global specialist Nicholas Vardy adds, "While the US markets are rising, Asian stocks are on fire." ETF expert Paul Tracy adds, "China funds have screamed to the top of the performance charts."

In large part, this strength is due to the country's stimulus program. Tracy points out, "To combat the sagging global economy, Chinese Premier Wen Jiabao orchestrated a massive 4 trillion yuan ($586 billion) stimulus package.